微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2014, Vol. 6 ›› Issue (2): 148-152.doi: 10.3969/j.issn.1674-5671.2014.02.10

• 临床研究 • 上一篇    下一篇

脂代谢异常与子宫内膜腺癌发生的相关因素研究

  

  1. 广西医科大学附属肿瘤医院妇瘤科；广西医科大学研究生学院
  • 出版日期:2014-06-25 发布日期:2014-07-08
  • 通讯作者: 张洁清 E-mail:zjq201008@hotmail.com
  • 基金资助:

    广西卫生厅科研基金资助项目（重2012094）

Lipid metabolism disorders as risk factors for endometrial adenocarcinoma

  • Online:2014-06-25 Published:2014-07-08

PDF (PC)

492

赞

摘要： 目的 通过分析子宫内膜腺癌（endometrial adenocarcinoma，EMA）患者的代谢指标，探讨脂代谢异常与子宫内膜腺癌发生的关系。方法 收集68例子宫内膜腺癌患者（内膜癌组）和同期61例正常子宫内膜健康体检者（对照组）的临床资料，检测两组的血脂代谢指标、空腹血糖（fasting plasma glucose，FPG）、空腹血清胰岛素（ fasting serum insulin，FINS）及稳态模型评估的胰岛素抵抗（homeostasis model assessment for insulin resistance，HOMA-IR）水平的差异。采用非条件logistic回归模型分析发生子宫内膜腺癌的危险因素，并探讨其与子宫内膜腺癌临床病理特征的关系。结果 内膜癌组的各项血脂指标、FINS和HOMA-IR均高于正常对照组（P均＜0.05）；甘油三酯（triglycerides，TG）、FINS、HOMA-IR与子宫内膜腺癌的临床病理特征无明显相关，差异均无统计学意义（P均>0.05）。结论 体质指数、腰围、TG、FINS和HOMA-IR与EMA的发生密切相关。FINS、TG升高和存在HOMA-IR可作为子宫内膜腺癌的预测因子。

关键词: 子宫肿瘤, 代谢综合征, 胰岛素抵抗

Abstract: Objective To explore possible relationships between lipid metabolism disorders and the occurrence of endometrial adenocarcinoma（EMA）. Methods A total of 68 patients with EMA and 61 control women were compared in terms of lipid metabolism indicators，fasting plasma glucose（FPG），fasting serum insulin（FINS） and homeostasis model assessment for insulin resistance（HOMA-IR）.Pooled odds ratios were estimated using non-conditional logistic regression to identify factors associated with risk of EMA and with clinicopathological features of the disease. Results The lipid indexes，FINS and HOMA-IR differed significantly between patients with EMA and controls（P<0.05）.However，triglyceride levels，FINS，and HOMA-IR were not significantly associated with clinicopathological features of EMA（P>0.05）. Conclusions EMA occurrence was associated with elevated body mass index， triglycerides，FINS，waist circumference，HOMA-IR.Elevated FINS，triglycerides and HOMA-IR may be useful as predictors of endometrial carcinoma.

Key words:  Uterine neoplasm, Metabolic syndrome, Insulin resistance